Developing clinical trials for biosimilars

Area of Science:

• Pharmaceutical Sciences
• Clinical Pharmacology
• Regulatory Science

Background:

• Biosimilars present accessible, affordable alternatives to biologics for various diseases, including cancer.
• Unlike generics, biosimilars are highly similar but not identical to reference biologics due to molecular complexity.

Purpose of the Study:

• To review critical considerations for biosimilar clinical trials and regulatory evaluation.
• To discuss the scientific basis for biosimilar approval and post-market surveillance.

Main Methods:

• Physicochemical characterization and comparability exercises to establish molecular similarity.
• In vitro, in vivo, and pharmacokinetic/pharmacodynamic (PK/PD) studies.
• Robust pharmacovigilance strategies for ongoing safety monitoring.

Main Results:

• Demonstrating high similarity is key, but full characterization may be challenging.
• Regulatory guidance, clinical trial design, and indication extrapolation are crucial evaluation aspects.
• European and Canadian experiences offer insights into biosimilar development.

Conclusions:

• Biosimilars require a comprehensive evaluation framework, including analytical, clinical, and post-marketing data.
• Ensuring biosimilar safety and efficacy relies on demonstrating similarity and continuous monitoring.
• Regulatory pathways facilitate the development and approval of biosimilars, enhancing patient access.